



## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Clinical Oncology*

**Manuscript NO:** 67608

**Title:** Immunotherapy combinations and chemotherapy sparing schemes in first line non-small cell lung cancer

**Provenance and peer review:** Invited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 05402718

**Position:** Peer Reviewer

**Academic degree:** PhD

**Professional title:** Assistant Professor, Research Associate

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** Spain

**Manuscript submission date:** 2021-04-28

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-06-21 05:30

**Reviewer performed review:** 2021-06-22 03:09

**Review time:** 21 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



<b>Peer-reviewer statements</b>	Peer-Review: [ <input checked="" type="checkbox"/> ] Anonymous [ <input type="checkbox"/> ] Onymous Conflicts-of-Interest: [ <input type="checkbox"/> ] Yes [ <input checked="" type="checkbox"/> ] No
---------------------------------	---

### **SPECIFIC COMMENTS TO AUTHORS**

In the present study, Sereno et al. reviewed immunotherapy combinations and chemotherapy sparing schemes in first line non-small cell lung cancers. Although there is some interesting, there are some comments for the authors. 1. Introduction is simple, please also add some information about the basic information of NSCLC and the current immunotherapy for NSCLC. Two key reviews are recommended for you, PMID: 33653420 and PMID: 33643442. 2. The basic writing needs to be improved. For example, in the introduction, Anti-PD-L1/PD-1 and anti-CTLA-4 should use full name in the first time. Authors should revise it throughout the draft. 3. “although in the d- IT the median OS of 11.9 months was shorter than that obtained with CT”, why have highlight information. What is “the d- IT”? Please carefully check the manuscript. 4. The authors must put the p values to all the tables describing the OS, PFS in different clinical trials. 5.

The challenge of current Immunotherapy combinations and chemotherapy in NSCLC should be added. 6. A schematic diagram should be provided about how PD-1/PDL-1 interact with immune cells to combat NSCLC. This is important. 7. The language is needed to be improved. 8. In table 1 and table 2, the more information should be provided.